Browse MAP2K5

Summary
SymbolMAP2K5
Namemitogen-activated protein kinase kinase 5
Aliases MEK5; MAPKK5; HsT17454; PRKMK5; MAP kinase kinase 5; MAP kinase kinase MEK5b; MAPK/ERK kinase 5; MAPKK 5; ME ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00564 PB1 domain
PF00069 Protein kinase domain
Function

Acts as a scaffold for the formation of a ternary MAP3K2/MAP3K3-MAP3K5-MAPK7 signaling complex. Activation of this pathway appears to play a critical role in protecting cells from stress-induced apoptosis, neuronal survival and cardiac development and angiogenesis.

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0001525 angiogenesis
GO:0001558 regulation of cell growth
GO:0001667 ameboidal-type cell migration
GO:0001818 negative regulation of cytokine production
GO:0002040 sprouting angiogenesis
GO:0002042 cell migration involved in sprouting angiogenesis
GO:0007162 negative regulation of cell adhesion
GO:0007369 gastrulation
GO:0007507 heart development
GO:0010466 negative regulation of peptidase activity
GO:0010470 regulation of gastrulation
GO:0010594 regulation of endothelial cell migration
GO:0010596 negative regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010633 negative regulation of epithelial cell migration
GO:0010951 negative regulation of endopeptidase activity
GO:0016049 cell growth
GO:0016525 negative regulation of angiogenesis
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0030307 positive regulation of cell growth
GO:0030336 negative regulation of cell migration
GO:0032088 negative regulation of NF-kappaB transcription factor activity
GO:0032147 activation of protein kinase activity
GO:0032602 chemokine production
GO:0032637 interleukin-8 production
GO:0032642 regulation of chemokine production
GO:0032677 regulation of interleukin-8 production
GO:0032682 negative regulation of chemokine production
GO:0032717 negative regulation of interleukin-8 production
GO:0033674 positive regulation of kinase activity
GO:0034113 heterotypic cell-cell adhesion
GO:0034114 regulation of heterotypic cell-cell adhesion
GO:0034115 negative regulation of heterotypic cell-cell adhesion
GO:0034405 response to fluid shear stress
GO:0034616 response to laminar fluid shear stress
GO:0038034 signal transduction in absence of ligand
GO:0040013 negative regulation of locomotion
GO:0042035 regulation of cytokine biosynthetic process
GO:0042036 negative regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042228 interleukin-8 biosynthetic process
GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0043534 blood vessel endothelial cell migration
GO:0043535 regulation of blood vessel endothelial cell migration
GO:0043537 negative regulation of blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0045414 regulation of interleukin-8 biosynthetic process
GO:0045415 negative regulation of interleukin-8 biosynthetic process
GO:0045765 regulation of angiogenesis
GO:0045860 positive regulation of protein kinase activity
GO:0045861 negative regulation of proteolysis
GO:0045927 positive regulation of growth
GO:0045995 regulation of embryonic development
GO:0048514 blood vessel morphogenesis
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051271 negative regulation of cellular component movement
GO:0051346 negative regulation of hydrolase activity
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0060759 regulation of response to cytokine stimulus
GO:0060761 negative regulation of response to cytokine stimulus
GO:0070375 ERK5 cascade
GO:0070586 cell-cell adhesion involved in gastrulation
GO:0070587 regulation of cell-cell adhesion involved in gastrulation
GO:0071498 cellular response to fluid shear stress
GO:0071499 cellular response to laminar fluid shear stress
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072567 chemokine (C-X-C motif) ligand 2 production
GO:0090049 regulation of cell migration involved in sprouting angiogenesis
GO:0090051 negative regulation of cell migration involved in sprouting angiogenesis
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:1901099 negative regulation of signal transduction in absence of ligand
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1903670 regulation of sprouting angiogenesis
GO:1903671 negative regulation of sprouting angiogenesis
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000117 negative regulation of cysteine-type endopeptidase activity
GO:2000146 negative regulation of cell motility
GO:2000181 negative regulation of blood vessel morphogenesis
GO:2000341 regulation of chemokine (C-X-C motif) ligand 2 production
GO:2000342 negative regulation of chemokine (C-X-C motif) ligand 2 production
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
GO:2001239 regulation of extrinsic apoptotic signaling pathway in absence of ligand
GO:2001240 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0004713 protein tyrosine kinase activity
GO:0005057 receptor signaling protein activity
Cellular Component GO:0005819 spindle
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04540 Gap junction
hsa04722 Neurotrophin signaling pathway
hsa04921 Oxytocin signaling pathway
Reactome R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-162582: Signal Transduction
R-HSA-166520: Signalling by NGF
R-HSA-198765: Signalling to ERK5
Summary
SymbolMAP2K5
Namemitogen-activated protein kinase kinase 5
Aliases MEK5; MAPKK5; HsT17454; PRKMK5; MAP kinase kinase 5; MAP kinase kinase MEK5b; MAPK/ERK kinase 5; MAPKK 5; ME ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MAP2K5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolMAP2K5
Namemitogen-activated protein kinase kinase 5
Aliases MEK5; MAPKK5; HsT17454; PRKMK5; MAP kinase kinase 5; MAP kinase kinase MEK5b; MAPK/ERK kinase 5; MAPKK 5; ME ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MAP2K5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMAP2K5
Namemitogen-activated protein kinase kinase 5
Aliases MEK5; MAPKK5; HsT17454; PRKMK5; MAP kinase kinase 5; MAP kinase kinase MEK5b; MAPK/ERK kinase 5; MAPKK 5; ME ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MAP2K5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.7790.000228
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.0970.497
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5480.642
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1140.639
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1910.907
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0120.995
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1260.648
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0660.956
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1980.884
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5460.664
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7480.686
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0060.903
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MAP2K5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMAP2K5
Namemitogen-activated protein kinase kinase 5
Aliases MEK5; MAPKK5; HsT17454; PRKMK5; MAP kinase kinase 5; MAP kinase kinase MEK5b; MAPK/ERK kinase 5; MAPKK 5; ME ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAP2K5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMAP2K5
Namemitogen-activated protein kinase kinase 5
Aliases MEK5; MAPKK5; HsT17454; PRKMK5; MAP kinase kinase 5; MAP kinase kinase MEK5b; MAPK/ERK kinase 5; MAPKK 5; ME ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAP2K5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAP2K5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMAP2K5
Namemitogen-activated protein kinase kinase 5
Aliases MEK5; MAPKK5; HsT17454; PRKMK5; MAP kinase kinase 5; MAP kinase kinase MEK5b; MAPK/ERK kinase 5; MAPKK 5; ME ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAP2K5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMAP2K5
Namemitogen-activated protein kinase kinase 5
Aliases MEK5; MAPKK5; HsT17454; PRKMK5; MAP kinase kinase 5; MAP kinase kinase MEK5b; MAPK/ERK kinase 5; MAPKK 5; ME ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MAP2K5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMAP2K5
Namemitogen-activated protein kinase kinase 5
Aliases MEK5; MAPKK5; HsT17454; PRKMK5; MAP kinase kinase 5; MAP kinase kinase MEK5b; MAPK/ERK kinase 5; MAPKK 5; ME ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MAP2K5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMAP2K5
Namemitogen-activated protein kinase kinase 5
Aliases MEK5; MAPKK5; HsT17454; PRKMK5; MAP kinase kinase 5; MAP kinase kinase MEK5b; MAPK/ERK kinase 5; MAPKK 5; ME ......
Chromosomal Location15q22.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MAP2K5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.